Prasugrel and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Prasugrel
Apixaban
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Prasugrel (Effient) and apixaban (Eliquis) both make your blood less likely to clot, just in different ways. Prasugrel keeps platelets from sticking together, and apixaban slows one of the clotting proteins. When you take them together, those effects add up, so your risk of bleeding goes up. Doctors sometimes prescribe both on purpose, but it does need care.
Watch for things like unusual bruising, pink or red urine, black or bloody stools, nosebleeds that won't stop, or coughing up blood. If you see heavy bleeding, get emergency help right away. The good news: your care team can manage this by watching you closely and adjusting your plan. Don't stop either drug on your own, just talk with your pharmacist or doctor.
Effect: Additive pharmacodynamic bleeding risk from combining an irreversible P2Y12 antiplatelet (prasugrel) with a direct factor Xa inhibitor (apixaban). Both act on hemostasis; no CYP or transporter interaction drives this.
- Direction: Increased bleeding risk, potentially serious or fatal.
- Evidence: Theoretical, but mechanism is well established. Severity major.
- Onset: Unspecified; effect present while both are active. Apixaban PD persists at least 24 hours after the last dose.
- Management: Promptly evaluate any signs of blood loss. Discontinue apixaban with active pathological hemorrhage. A specific anti-FXa reversal agent is available; PCC, aPCC, or rFVIIa may be considered. Note clotting tests (PT/INR/aPTT, anti-FXa) are not useful for monitoring after PCC.
What happens
Increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Taking apixaban together with antiplatelet drugs raises the likelihood of bleeding1. In a patient receiving both anticoagulant and antiplatelet therapy, any indication of blood loss should be assessed without delay2. Apixaban should be stopped in patients experiencing active pathological hemorrhage. Patients should be counseled about the signs and symptoms of blood loss and instructed to report them right away or to seek care at an emergency room. Apixaban should be stopped in patients experiencing active pathological hemorrhage. There is an agent that reverses the anti-factor Xa activity of apixaban. Apixaban's pharmacodynamic effect is anticipated to remain for a minimum of 24 hours following the final dose. Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are administered, using a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity to track the anticoagulation effect of apixaban offers no benefit and is not advised. The absorption of apixaban is decreased by activated oral charcoal, which consequently reduces the plasma concentration of apixaban1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
If both medicines are prescribed together, that is often intentional. The main job is watching for bleeding.
- Keep taking both as prescribed unless your prescriber tells you otherwise. Do not stop on your own.
- Learn the warning signs: unusual bruising, bleeding gums, nosebleeds, pink or red urine, black or bloody stools, coughing or vomiting blood, or severe headache.
- Report bleeding right away, and for heavy or uncontrolled bleeding go to an emergency room.
- Your team may monitor you more closely, and doses may be individualized to your situation. A reversal agent for apixaban is available if serious bleeding occurs.
Ask your pharmacist to review all your medicines, including over-the-counter pain relievers like NSAIDs, which can add to bleeding risk.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) A clinical trial involving high-risk patients following acute coronary syndrome who were treated with aspirin or a combination of aspirin and clopidogrel (APPRAISE-2) was stopped ahead of schedule because apixaban produced a greater incidence of bleeding than placebo. Among patients on single antiplatelet therapy, the rate of ISTH major bleeding was 2.8% per year with apixaban compared with 0.6% per year with placebo, whereas among those on dual antiplatelet therapy it was 5.9% per year with apixaban compared with 2.5% per year with placebo 1.
b) In a clinical trial (ARISTOTLE), among patients taking apixaban, adding aspirin raised the bleeding risk from 1.8% per year to 3.4% per year, and adding both aspirin and warfarin raised the bleeding risk from 2.7% per year to 4.6% per year; use of dual antiplatelet therapy with apixaban was limited (2.3%) in this trial 1.
c) In a retrospective study, the combined use of a direct oral anticoagulant (DOAC) with antiplatelet therapy (APT; n=78) compared with DOAC therapy alone (n=329) did not significantly change the rate of major bleeding (1.3% vs 1.2%) or clinically relevant non-major bleeding (10.2% vs 6.4%) across 6 months of treatment. The patients were predominantly Caucasian men with a mean age of 63.7 years. Those receiving concurrent APT had significantly higher mean body mass index (30.7 vs 28.4), higher mean CHA2DS2-VASc score (4.28 vs 3.85), and were more likely to have diabetes (26.9% vs 17.3%) than those on DOAC monotherapy. DOACs were prescribed for VTE treatment or atrial fibrillation and included apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%). Single antiplatelet therapy was used in 94.9% (74 patients), with aspirin 81 mg once daily being the most common regimen (69 patients). Additional APT regimens comprised aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT with aspirin 81 mg and clopidogrel 75 mg daily (4 patients) 3.
Common questions
Can I take Prasugrel and Apixaban together?
Prasugrel and apixaban both thin the blood in different ways, so together they raise your bleeding risk. Keep taking both as prescribed, know the signs of bleeding, and seek emergency care for heavy bleeding. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Prasugrel and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Prasugrel and Apixaban interaction managed?
If both medicines are prescribed together, that is often intentional. The main job is watching for bleeding. Keep taking both as prescribed unless your prescriber tells you otherwise. Do not stop on your own. Learn the warning signs: unusual bruising, bleeding gums, nosebleeds, pink or red urine, black or bloody stools, coughing or vomiting blood, or severe headache. Report bleeding right away, an… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Prasugrel or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
- Product Information: SAVAYSA(R) oral tablets, edoxaban oral tablets. Daiichi Sankyo Inc (per FDA), Basking Ridge, NJ, 2023. DailyMed
- Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
Keep reading about Prasugrel
Keep reading about Apixaban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist